financetom
Business
financetom
/
Business
/
Oregon's health authority reviewing UnitedHealth's acquisition of Amedisys
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Oregon's health authority reviewing UnitedHealth's acquisition of Amedisys
Mar 19, 2024 4:11 PM

(Reuters) - Amedisys ( AMED ) said on Tuesday Oregon's health authority has started a review of UnitedHealth Group's ( UNH ) $3.3 billion acquisition of the home health and hospice caregiver.

UnitedHealth ( UNH ) had announced the acquisition in June, after competing with Option Care Health.

The acquisition was meant to help expand UnitedHealth's ( UNH ) presence in home healthcare, a business it bolstered through a $5.4 billion deal to buy Amedisys' ( AMED ) rival, LHC Group, last year.

Oregon's notice said it expects to complete the review within 180 days within receipt of a transaction form, which the agency had confirmed in December, according to Amedisys ( AMED ).

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Lab at Heart of Zantac Cancer Claims Files Whistleblower Lawsuit Against GSK
Lab at Heart of Zantac Cancer Claims Files Whistleblower Lawsuit Against GSK
May 20, 2024
03:51 PM EDT, 05/20/2024 (MT Newswires) -- The independent lab that raised concerns about GSK's (GSK) Zantac heartburn medication has filed a whistleblower lawsuit against the UK drugmaker, alleging the company hid the drug's cancer risks for decades. The suit, filed in the US District Court for the Eastern District of Pennsylvania, by Valisure alleges GSK concealed data from the...
Regeneron, Sanofi Disclose Positive Results for Lung Disease Treatment Candidate
Regeneron, Sanofi Disclose Positive Results for Lung Disease Treatment Candidate
May 20, 2024
03:33 PM EDT, 05/20/2024 (MT Newswires) -- Regeneron Pharmaceuticals ( REGN ) and Sanofi ( SNY ) said Monday the phase 3 trial of its lung disease treatment Dupixent as an add-on maintenance treatment in adults with uncontrolled chronic obstructive pulmonary disease, or COPD, met primary endpoint. The trial showed a 34% reduction in moderate or severe COPD exacerbations over...
Market Chatter: Rio Tinto Declares 'Force Majeure' on Australian Alumina Shipments Amid Gas Shortage
Market Chatter: Rio Tinto Declares 'Force Majeure' on Australian Alumina Shipments Amid Gas Shortage
May 20, 2024
03:49 PM EDT, 05/20/2024 (MT Newswires) -- Rio Tinto (RIO) has declared force majeure on alumina shipments from its Queensland, Australia refineries due to gas shortages, Bloomberg reported Monday, citing people familiar with the situation. The company notified clients of the decision on Monday, the people told Bloomberg. The shortage has affected the mining company's Yarwun refinery and Queensland Alumina,...
Dutch Bros Insider Sold Shares Worth $16,235,448, According to a Recent SEC Filing
Dutch Bros Insider Sold Shares Worth $16,235,448, According to a Recent SEC Filing
May 20, 2024
03:42 PM EDT, 05/20/2024 (MT Newswires) -- Travis Boersma, 10% Owner, Director, Executive Chairman of Board, on May 16, 2024, sold 439,510 shares in Dutch Bros ( BROS ) for $16,235,448. Following the Form 4 filing with the SEC, Boersma has control over a total of 1,039,239 shares of the company, with 1,039,239 controlled indirectly. SEC Filing: https://www.sec.gov/Archives/edgar/data/1866581/000186658124000170/xslF345X03/wk-form4_1716233953.xml Price: 36.64,...
Copyright 2023-2026 - www.financetom.com All Rights Reserved